Why Now

Three macro forces converging
in a narrow window.

Three structural shifts are creating a window for the right infrastructure to dominate this space — and that window is open now.

1
Regulatory Shift
The EU Health Data Space goes live 2025–2026.

Cross-border secondary use of health data is now legally enabled for the first time across the EU. The largest structural change to health data governance in a generation. Platforms with compliant infrastructure in place first will capture the market. UndosaTech is designed natively for this moment.

Live Signal — April 2026
The FDA sent messages to 2,200+ sponsors about unreported trial results — 29.6% of applicable trials have still never submitted required data. The agency is escalating toward formal enforcement including civil monetary penalties of up to $15,107 per day.
2
Technology Shift
Foundation models are commoditised. Data is the moat.

GPT-4 and its successors have democratised model capability. Every organisation now has access to state-of-the-art AI. The competitive advantage in biomedical AI no longer lies in the model — it lies entirely in proprietary, high-quality, labelled datasets. UndosaTech builds the infrastructure others depend on to access it.

The Strategic Reality
Chalmers and Glasziou estimated 85% of biomedical research investment is avoidably wasted. The primary driver is inaccessible data — exactly what UndosaTech's federated architecture addresses without compromising governance.
3
Economic Shift
NHS institutions face acute financial pressure.

The royalty marketplace turns archived patient cohorts into a sustainable revenue stream — resonating immediately with budget-constrained Trusts and universities. The incentive to participate is financial, not just altruistic. Adoption follows economic logic rather than goodwill.

The CNS Drug Development Crisis
Fewer than 10% of CNS drug candidates entering clinical trials ultimately reach the market. A Phase III Alzheimer's trial averages $370M to run and takes up to 8 years. Better cross-institutional data access at earlier stages is a direct lever on these failure rates.
Competitive Landscape

Specialisation,
not breadth.

The federated learning space includes well-funded players. UndosaTech focuses on a specific underserved wedge: vision science and neuroscience, with a governance-first reuse framework designed for NHS Trusts.

Owkin
General Biomedical AI
Broad federated platform across therapeutic areas. Strong in oncology. Not specialised for neuroscience or NHS governance structures.
Lifebit
Genomics & Biobank
Strong in genomics infrastructure. Less focused on neuroscience workflows or the data reuse cost-recovery model.
TriNetX
Clinical Trial Networks
Clinical trial patient matching. Centralised data model. Not designed for zero-trust federated architecture required by NHS IG.
UndosaTech
Vision Science & Neuroscience · NHS & EU
Deep specialisation in vision science and neuroscience. Governance-first reuse framework. NHS cost-recovery model. No-code AI for domain researchers.
Rhino Health
Federated Computing
General federated computing. US-focused. Does not address the NHS IG and EHDS compliance layer or the research data reuse programme.
National Initiatives
HDR UK, NHS DigiTrials
Public sector infrastructure. Slow-moving, not accessible to early-stage researchers. UndosaTech complements rather than competes.

The window is open now.

If you're an investor, researcher, or institution who sees the same convergence — we want to hear from you.

Get in Touch → See the Platform